IMI’s Antimicrobial Resistance (AMR) Accelerator programme comprises 7 projects with the shared goal of progressing the development of new medicines to treat or prevent resistant bacterial infections in Europe and worldwide. By 2025, AMR Accelerator projects will deliver up to 10 new preclinical candidates and up to 5 Phase II-ready compounds to address antibiotic resistant infections.
A pipeline of medicines for the treatment or prevention of antibiotic-resistant bacterial infections will be progressed. Data from EFPIA-funded clinical trials of anti-infective agents will be analysed to understand how preclinical data translates to clinical results.
A Capability Building Network (the COMBINE project) will coordinate the AMR Accelerator programme and in addition will carry out research to strengthen scientific knowledge in the AMR field.
The Tuberculosis (TB) Drug Development Network (the ERA4TB project) will work to accelerate the discovery of new combinations of drugs to treat TB.
The Portfolio Building Networks (the RespiriTB, RespiriNTM, TRIC-TB, GNA NOW and AB-Direct projects) will support collaborative efforts to discover, develop and advance new and innovative agents to prevent or treat AMR infections.